Laboratory Studies for Gout
For diagnosis, synovial fluid aspiration with crystal analysis is the gold standard and should be performed whenever possible; when crystal identification is not feasible, serum uric acid levels combined with renal function testing and cardiovascular risk assessment form the essential laboratory workup. 1
Diagnostic Laboratory Testing
Primary Diagnostic Test
- Synovial fluid analysis with crystal identification is strongly recommended for any patient with undiagnosed inflammatory arthritis, as monosodium urate (MSU) crystal identification remains the definitive diagnostic test 1
- This should be performed via joint aspiration or tophus aspirate when accessible 1
- Crystal identification has the highest diagnostic certainty and should be routinely undertaken before committing patients to lifelong urate-lowering therapy 1
Serum Uric Acid (Critical Caveat)
- Serum uric acid should be measured, but diagnosis should NOT be made on hyperuricemia alone 1
- While hyperuricemia is associated with gout, only 22% of patients with serum uric acid >9 mg/dL develop gout over 5 years 1
- Serum uric acid has limited diagnostic utility as a standalone test (positive likelihood ratio <3) 2
- However, it remains essential for monitoring treatment targets (goal <6 mg/dL or 0.36 mmol/L) 1
Management-Related Laboratory Testing
Mandatory Baseline Assessment
- Renal function testing is recommended in all patients with gout and/or hyperuricemia, as this impacts medication dosing and identifies an important comorbidity 1
- Cardiovascular risk factor assessment should be systematically performed, including screening for obesity, hypertension, ischemic heart disease, heart failure, diabetes, and dyslipidemia 1
Risk Factor Identification
Search for contributing factors to hyperuricemia in every patient 1:
- Chronic kidney disease markers (creatinine, eGFR)
- Medications that elevate uric acid (diuretics, low-dose aspirin, cyclosporine, tacrolimus)
- Metabolic syndrome components (glucose, lipid panel)
Monitoring During Treatment
- Serial serum uric acid levels to assess achievement of target <0.36 mmol/L (6 mg/dL), or <0.30 mmol/L (5 mg/dL) for tophaceous gout 1
- Renal function monitoring when using allopurinol, particularly in patients with renal impairment where close monitoring for adverse events is required 1
Clinical Context
The 2020 EULAR guidelines emphasize a three-step diagnostic approach: (1) MSU crystal identification, (2) clinical diagnosis when crystal identification is not possible, and (3) imaging when clinical diagnosis is uncertain 1. Laboratory testing supports but does not replace crystal identification for definitive diagnosis. The presence of hyperuricemia combined with typical clinical features (podagra, tophi, rapid symptom onset) has sensitivity and specificity >80% compared to crystal analysis, but this is insufficient to replace definitive testing 1.
Common pitfall: Relying solely on elevated serum uric acid for diagnosis leads to overdiagnosis, as hyperuricemia is present in many individuals who never develop gout 1. Conversely, serum uric acid can be normal during acute flares, so a normal level does not exclude gout 2.